IONIS PHARMACEUTICALS INC(NASDAQ:IONS) stock News

IONS Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - A Strong Technical Setup Worth Watching

4 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis to hold second quarter 2025 financial results webcast

18 days ago - By: Benzinga - Mentions: CHRW CTAS NKE MLCO

This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

19 days ago - By: Yahoo Finance - Mentions: NKE RJF GS HAS ...

Nike upgraded, Sportradar initiated: Wall Street's top analyst calls

19 days ago - By: Benzinga

10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know

23 days ago - By: Biogen Inc. - Mentions: BIIB

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

25 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

25 days ago - By: Biogen Inc. - Mentions: BIIB

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

25 days ago - By: Investor's Business Daily - Mentions: NVS BIIB

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?

a month ago - By: Yahoo Finance - Mentions: NVS BIIB

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

a month ago - By: Ionis Pharmaceuticals, Inc.

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

a month ago - By: Zacks Investment Research - Mentions: ESPR

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

a month ago - By: Yahoo Finance - Mentions: RXRX NVDA ZTS NLY ...

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today

2 months ago - By: Zacks Investment Research - Mentions: RXRX

Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?

2 months ago - By: Zacks Investment Research

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

2 months ago - By: Yahoo Finance - Mentions: HCA PANW TOL OPRX ...

Cantor Fitzgerald Upgrades HCA Healthcare, Inc.’s (HCA) Price Target, Citing Strategic Strengths

2 months ago - By: Zacks Investment Research - Mentions: AZN GSK BIIB

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

2 months ago - By: Yahoo Finance - Mentions: JPM

Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

2 months ago - By: Yahoo Finance - Mentions: VZ AMZN AAPG KO ...

Trump’s Tariffs: 7 Things To Do Now If You’re Worried About the Unpredictable Stock Markets

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis to host 2025 virtual Annual Meeting of Stockholders

3 months ago - By: Zacks Investment Research - Mentions: AZN NVS BIIB

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

3 months ago - By: Zacks Investment Research

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

3 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis reports first quarter 2025 financial results

3 months ago - By: Ionis Pharmaceuticals, Inc.

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

3 months ago - By: Zacks Investment Research

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

3 months ago - By: Ionis Pharmaceuticals, Inc.

IONIS PHARMACEUTICALS INC (IONS) Stock News

IONS Latest News, Press Relases and Analysis

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - A Strong Technical Setup Worth Watching

Ionis to hold second quarter 2025 financial results webcast

This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Nike upgraded, Sportradar initiated: Wall Street's top analyst calls

10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today

Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

Cantor Fitzgerald Upgrades HCA Healthcare, Inc.’s (HCA) Price Target, Citing Strategic Strengths

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

Trump’s Tariffs: 7 Things To Do Now If You’re Worried About the Unpredictable Stock Markets

Ionis to host 2025 virtual Annual Meeting of Stockholders

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

Ionis reports first quarter 2025 financial results

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis to hold first quarter 2025 financial results webcast